Directly observed therapy for chronic hepatitis C: A randomized clinical trial in the prison setting

Gastroenterologia y Hepatologia

Volumn 37, Issue 8, 2014, Pages 443-451

  Saiz de la Hoya, Pablo ^a   Portilla, Joaquín ^b   Marco, Andrés ^c   García Guerrero, Julio ^d   Faraco, Inmaculada ^d   Antón, José ^e   de Juan, José ^f   Pozo, Edelmira ^g  

^a Servicios Médicos Centro Penitenciario Fontcalent   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^c Centro Penitenciario de Mujeres   (Spain)

^d Servicios Médicos Centro Penitenciario   (Spain)

^e Centro Penitenciario de Albolote   (Spain)

^f Servicios Médicos Centro Penitenciario Córdoba   (Spain)

^g Servicios Médicos Centro Penitenciario Villabona   (Spain)

Author keywords

Chronic hepatitis C; Directly observed therapy; HCV; Pegylated interferon; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; PEGYLATED INTERFERON ALPHA2A; RECOMBINANT INTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DIRECTLY OBSERVED THERAPY; DRUG USE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; PRISON; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; CLINICAL TRIAL; HEPATITIS C, CHRONIC;

ADULT; ANTIVIRAL AGENTS; DIRECTLY OBSERVED THERAPY; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; POLYETHYLENE GLYCOLS; PRISONS; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84907684161     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/j.gastrohep.2014.03.004     Document Type: Article

References (25)

1. Imperial J.C. Chronic hepatitis C in the state prison system: insights into the problems and possible solutions. Expert Rev Gastroenterol Hepatol 2010, 4:355-364.
2. Vescio M.F., Longo B., Babudieri S., Starnini G., Carbonara S., Rezza G., et al. Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis. J Epidemiol Community Health 2008, 62:305-313.
3. Abad-Perez I., Carbonell-Franco E., Navarro-Garcia D., Roig-Sena F.J., Salazar A. Evolution of the main diagnoses of hospital discharges amongst the prison population in Valencia, 2000-2009. Rev Esp Sanid Penit 2011, 13:38-43.
4. Saiz de la Hoya P., Marco A., Garcia-Guerrero J., Rivera A. Hepatitis C and B prevalence in Spanish prisons. Eur J Clin Microbiol Infect Dis 2011, 30:857-862.
5. Murcia J., Portilla J., Bedia M., Palazon J.M., Sanchez-Paya J., Saiz de la Hoya P., et al. Chronic hepatitis C virus infection and associated liver disease among the inmates of a Spanish prison. Enferm Infecc Microbiol Clin 2009, 27:206-212.
6. Rosen H.R. Clinical practice. Chronic hepatitis C infection. N Engl J Med 2011, 364:2429-2438.
7. Global Alert and Response (GAR): Hepatitis C. World Health Organization [14 February 2012]; Available from:. http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index3.html%23diagnosis.
8. Harzke A.J., Baillargeon J.G., Kelley M.F., Diamond P.M., Goodman K.J., Paar D.P. HCV-related mortality among male prison inmates in Texas, 1994-2003. Ann Epidemiol 2009, 19:582-589.
9. Saiz de la Hoya-Zamacola P., Marco-Mourino A., Clemente-Ricote G., Portilla-Sogorb J., Boix-Martinez V., Nunez-Martinez O., et al. Expert recommendations for the diagnosis and treatment of chronic hepatitis C infection in the prison setting. Gastroenterol Hepatol 2006, 29:551-559.
10. Ferenci P., Fried M.W., Shiffman M.L., Smith C.I., Marinos G., Goncales F.L., et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005, 43:425-433.
11. Sterling R.K., Hofmann C.M., Luketic V.A., Sanyal A.J., Contos M.J., Mills A.S., et al. Treatment of chronic hepatitis C virus in the Virginia department of corrections: can compliance overcome racial differences to response?. Am J Gastroenterol 2004, 99:866-872.
12. Pugh R.N., Murray-Lyon I.M., Dawson J.L., Pietroni M.C., Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973, 60:646-649.
13. Child C., Turcotte J. The liver and portal hypertension. Surgery and Portal Hypertension 1964, 50-58. W.B. Saunders, Philadelphia, USA. C.I. Child (Ed.).
14. Bonkovsky H.L., Tice A.D., Yapp R.G., Bodenheimer H.C., Monto A., Rossi S.J., et al. Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration. Am J Gastroenterol 2008, 103:2757-2765.
15. Maru D.S., Bruce R.D., Basu S., Altice F.L. Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations. Clin Infect Dis 2008, 47:952-961.
16. Farley J.D., Wong V.K., Chung H.V., Lim E., Walters G., Farley T.A., et al. Treatment of chronic hepatitis C in Canadian prison inmates. Can J Gastroenterol 2005, 19:153-156.
17. Chew K.W., Allen S.A., Taylor L.E., Rich J.D., Feller E. Treatment outcomes with pegylated interferon and ribavirin for male prisoners with chronic hepatitis C. J Clin Gastroenterol 2009, 43:686-691.
18. Sabbatani S., Giuliani R., Manfredi R. Combined pegylated interferon and ribavirin for the management of chronic hepatitis C in a prison setting. Braz J Infect Dis 2006, 10:274-278.
19. Boonwaat L., Haber P.S., Levy M.H., Lloyd A.R. Establishment of a successful assessment and treatment service for Australian prison inmates with chronic hepatitis C. Med J Aust 2010, 192:496-500.
20. Grebely J., Raffa J.D., Meagher C., Duncan F., Genoway K.A., Khara M., et al. Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. J Gastroenterol Hepatol 2007, 22:1519-1525.
21. Litwin A.H., Harris K.A., Nahvi S., Zamor P.J., Soloway I.J., Tenore P.L., et al. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. J Subst Abuse Treat 2009, 37:32-40.
22. Waizmann M., Ackermann G. High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin. J Subst Abuse Treat 2010, 38:338-345.
23. Marco Mourino A., da Silva Moran A., Ortiz Seuma J., Sole Carbo C., Roget Alemany M., Sarriera Gracia C., et al. Predictors of adherence to treatment of chronic hepatitis C in drug-dependent inmate patients in four prisons in Barcelona, Spain. Rev Esp Salud Publica 2010, 84:423-431.
24. Farley J., Vasdev S., Fischer B., Haydon E., Rehm J., Farley T.A. Feasibility and outcome of HCV treatment in a Canadian federal prison population. Am J Public Health 2005, 95:1737-1739.
25. Saiz de la Hoya P., Marco A., García-Guerrero J., Faraco I., Antón J., Portilla J., et al. Comparative study to assess the efficacy of directly observed ribavirin therapy vs. self-administered ribavirin therapy, both with directly observed pegylated interferon alpha-2a, among prison population with chronic hepatitis C (Clinical Trial RIBADOT). XIV Congreso de la Sociedad Española de Enfermedades Infecciosas y Microbiologia Clinica (SEIMC) 2010, 143-144.